Skip to content
Biodatica
Start free

Disc Medicine, Inc

Duarte, California

OncologyPhase IIIListed · IRON

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Expanded Access Program of Bitopertin For Participants With EPP or XLP

4d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jul 15, 2026

    Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) · AVAILABLE · sponsor: Disc Medicine, Inc · Expanded Access Program of Bitopertin For Participants With EPP or XLP

    ClinicalTrials.gov · NCT07603401 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Feb 20, 2026

    Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia · RECRUITING · sponsor: Disc Medicine, Inc · Study of DISC-0974-201 in Participants With IBD and Anemia

    ClinicalTrials.gov · NCT07368972 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Aug 12, 2025

    Polycythemia Vera (PV) · RECRUITING · sponsor: Disc Medicine, Inc · A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

    ClinicalTrials.gov · NCT06985147 (opens the source filing in a new tab)

  4. Trial

    PHASE2/PHASE3 registered

    Aug 31, 2023

    Erythropoietic Protoporphyria · ENROLLING_BY_INVITATION · sponsor: Disc Medicine, Inc · HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

    ClinicalTrials.gov · NCT05883748 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Oct 31, 2022

    Erythropoietic Protoporphyria · COMPLETED · sponsor: Disc Medicine, Inc · Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

    ClinicalTrials.gov · NCT05308472 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Jun 6, 2022

    Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes · RECRUITING · sponsor: Disc Medicine, Inc · Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

    ClinicalTrials.gov · NCT05320198 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources